Biogen Inc. (BVMF:BIIB34)

Biogen Statistics

Total Valuation

Biogen has a market cap or net worth of BRL 154.11 billion. The enterprise value is 166.68 billion.

Market Cap	154.11B
Enterprise Value	166.68B

Important Dates

The last earnings date was Friday, February 6, 2026.

Earnings Date	Feb 6, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+0.82%
Shares Change (QoQ)	-0.27%
Owned by Insiders (%)	0.17%
Owned by Institutions (%)	96.95%
Float	146.32M

Valuation Ratios

The trailing PE ratio is 21.64 and the forward PE ratio is 13.24.

PE Ratio	21.64
Forward PE	13.24
PS Ratio	2.83
PB Ratio	1.53
P/TBV Ratio	10.81
P/FCF Ratio	13.64
P/OCF Ratio	12.69
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.57, with an EV/FCF ratio of 14.76.

EV / Earnings	23.41
EV / Sales	3.23
EV / EBITDA	8.57
EV / EBIT	11.31
EV / FCF	14.76

Financial Position

The company has a current ratio of 2.68, with a Debt / Equity ratio of 0.36.

Current Ratio	2.68
Quick Ratio	1.70
Debt / Equity	0.36
Debt / EBITDA	1.79
Debt / FCF	3.25
Interest Coverage	10.56

Financial Efficiency

Return on equity (ROE) is 7.39% and return on invested capital (ROIC) is 11.19%.

Return on Equity (ROE)	7.39%
Return on Assets (ROA)	6.14%
Return on Invested Capital (ROIC)	11.19%
Return on Capital Employed (ROCE)	10.82%
Weighted Average Cost of Capital (WACC)	4.80%
Revenue Per Employee	7.26M
Profits Per Employee	949,506
Employee Count	7,605
Asset Turnover	0.34
Inventory Turnover	0.90

Taxes

In the past 12 months, Biogen has paid 1.45 billion in taxes.

Income Tax	1.45B
Effective Tax Rate	16.94%

Stock Price Statistics

The stock price has increased by +17.12% in the last 52 weeks. The beta is 0.16, so Biogen's price volatility has been lower than the market average.

Beta (5Y)	0.16
52-Week Price Change	+17.12%
50-Day Moving Average	155.59
200-Day Moving Average	145.55
Relative Strength Index (RSI)	59.27
Average Volume (20 Days)	56

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.36

Income Statement

In the last 12 months, Biogen had revenue of BRL 54.48 billion and earned 7.12 billion in profits. Earnings per share was 48.42.

Revenue	54.48B
Gross Profit	43.01B
Operating Income	15.55B
Pretax Income	8.57B
Net Income	7.12B
EBITDA	19.85B
EBIT	15.55B
Earnings Per Share (EPS)	48.42

Balance Sheet

The company has 21.02 billion in cash and 36.67 billion in debt, with a net cash position of -13.27 billion.

Cash & Cash Equivalents	21.02B
Total Debt	36.67B
Net Cash	-13.27B
Net Cash Per Share	n/a
Equity (Book Value)	100.56B
Book Value Per Share	685.00
Working Capital	30.98B

Cash Flow

In the last 12 months, operating cash flow was 12.14 billion and capital expenditures -847.13 million, giving a free cash flow of 11.30 billion.

Operating Cash Flow	12.14B
Capital Expenditures	-847.13M
Free Cash Flow	11.30B
FCF Per Share	n/a

Margins

Gross margin is 78.95%, with operating and profit margins of 28.55% and 13.07%.

Gross Margin	78.95%
Operating Margin	28.55%
Pretax Margin	15.74%
Profit Margin	13.07%
EBITDA Margin	36.44%
EBIT Margin	28.55%
FCF Margin	20.73%

Dividends & Yields

Biogen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.82%
Shareholder Yield	-0.82%
Earnings Yield	4.62%
FCF Yield	7.33%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Biogen has an Altman Z-Score of 2.97 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.97
Piotroski F-Score	6